The study is divided into two parts:
Part 1:To evaluate the safety and tolerability of nal-IRI + 5FU/LV +
oxaliplatin. To characterize dose-limiting toxicities (DLTs) associated with nal-IRI + 5FU/LV + oxaliplatin and determine the Part 2 dose of the
Part 2:To assess the efficacy of nal-IRI-containing regimens in first-line
metastatic pancreatic cancer patients compared to nab-paclitaxel +
gemcitabine using the progression-free survival (PFS) rate at 24 weeks.